A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer Full Text
Investigational New Drugs, 07/31/2012
Clinical Article
Hudes G et al. – The results suggest that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with castration–resistant prostate cancer (CRPC).



